Business Description
ISIN : US10806X1028
Total Employee Number:
839Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.29 | |||||
Equity-to-Asset | -2.07 | |||||
Debt-to-Equity | -0.99 | |||||
Debt-to-EBITDA | -5.06 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -2.84 | |||||
Beneish M-Score | -1.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 70.7 | |||||
3-Year EBITDA Growth Rate | -2.1 | |||||
3-Year EPS without NRI Growth Rate | -7.4 | |||||
3-Year FCF Growth Rate | 6.3 | |||||
3-Year Book Growth Rate | -8.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 70.68 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 23.13 | |||||
9-Day RSI | 34.6 | |||||
14-Day RSI | 41.97 | |||||
3-1 Month Momentum % | 26.61 | |||||
6-1 Month Momentum % | 26.53 | |||||
12-1 Month Momentum % | 69.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.23 | |||||
Quick Ratio | 1.17 | |||||
Cash Ratio | 0.81 | |||||
Days Inventory | 286.03 | |||||
Days Sales Outstanding | 81.14 | |||||
Days Payable | 252.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.9 | |||||
Shareholder Yield % | -1 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 94.44 | |||||
Operating Margin % | -67.01 | |||||
Net Margin % | -97.03 | |||||
EBITDA Margin % | -69.1 | |||||
FCF Margin % | -61.4 | |||||
OCF Margin % | -60.92 | |||||
ROA % | -61.74 | |||||
ROIC % | -107.65 | |||||
3-Year ROIIC % | -27.49 | |||||
ROC (Joel Greenblatt) % | -1627.45 | |||||
ROCE % | -77.41 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 20.88 | |||||
EV-to-EBIT | -33.65 | |||||
EV-to-Forward-EBIT | -44.91 | |||||
EV-to-EBITDA | -34 | |||||
EV-to-Forward-EBITDA | -46.25 | |||||
EV-to-Revenue | 23.49 | |||||
EV-to-Forward-Revenue | 17.09 | |||||
EV-to-FCF | -38.26 | |||||
Price-to-GF-Value | 0.51 | |||||
Earnings Yield (Greenblatt) % | -2.97 | |||||
FCF Yield % | -2.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BBIO
Peter Lynch Chart
Performance
Annualized Return %
Total Annual Return %
BridgeBio Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 713.069 | ||
| EPS (TTM) ($) | -3.57 | ||
| Beta | 0.7717 | ||
| 3-Year Sharpe Ratio | 0.73 | ||
| 3-Year Sortino Ratio | 1.4 | ||
| Volatility % | 34.53 | ||
| 14-Day RSI | 41.97 | ||
| 14-Day ATR ($) | 2.573001 | ||
| 20-Day SMA ($) | 81.772 | ||
| 12-1 Month Momentum % | 69.63 | ||
| 52-Week Range ($) | 48.78 - 93.415 | ||
| Shares Outstanding (Mil) | 195.49 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BridgeBio Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BridgeBio Pharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-24 16:30 | In 181 days | ||
| Annual report for 2026 | 2027-02-24 | In 180 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 | In 180 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-29 16:30 | In 63 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 62 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-10 16:30 | 84.48 (+0.91%) | ||
| Second quarter earnings results for 2026 | 2026-08-10 | 84.48 (+0.91%) | ||
| General meeting for 2026 | 2026-06-22 11:00 | 66.27 (-2.66%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 08:00 | 67.37 (-0.88%) | ||
| Guidance call for 2026 | 2026-06-04 11:05 | 65.48 (+3.23%) |
BridgeBio Pharma Inc Frequently Asked Questions
Guru Commentaries on NAS:BBIO
Bridgebio Pharma is a biotechnology company focused on rare diseases, especially heart-related conditions. The company’s lead drug was recently approved, and the launch has gone better than expected, indicating strong market potential and growth prospects. This positive trajectory in product launch and the focus on a niche market position Bridgebio as an attractive investment opportunity within the biotechnology sector.
Bridgebio Pharma is a biotechnology company focused on rare diseases, especially heart-related conditions. The company’s lead drug was recently approved, and the launch has gone better than expected. This positive momentum in product launch positions Bridgebio favorably within the biotechnology sector, indicating strong growth potential as they address unmet medical needs in rare diseases.
Bridgebio Pharma is a biotechnology company focused on rare diseases, especially heart-related conditions. The company’s lead drug was recently approved, and the launch has gone better than expected. This positive momentum in product launch positions Bridgebio favorably within the biotechnology sector, indicating strong growth potential and a solid market presence.
Press Release
Articles on BridgeBio Pharma Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
